YFY Biotech Management Company

Omni-ID Ltd. is a developer and supplier of passive ultra high frequency radio frequency identification (RFID) technology products, specializing in low-profile tags that perform reliably in challenging environments, including on metals and liquids. Founded in 2007 and based in Farnham, United Kingdom, the company offers a range of products such as the Max, Flex, Prox, and ProVIEW tags. These products cater to various applications including asset tracking in information technology, manufacturing, and retail sectors, as well as tool tracking and industrial device management. Omni-ID's technology ensures precise identification and management of high-value assets, making it a key player in the industrial Internet of Things and RFID markets.

TaiGen Biotechnology Co., Ltd. is a pharmaceutical company headquartered in Taipei, Taiwan, with additional operations in Beijing, China, and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of innovative therapeutics targeting infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug effective against drug-resistant pathogens; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, which treats influenza A and B. Additionally, TaiGen develops stem cell mobilizers for therapeutic applications in leukemia and offers a range of inhibitors for hepatitis C, as well as treatments for various bacterial infections. The company's focus on addressing unmet medical needs positions it as a significant player in the pharmaceutical industry.

TaiGen Biotechnology Co., Ltd. is a pharmaceutical company headquartered in Taipei, Taiwan, with additional operations in Beijing, China, and the United States. Founded in 2001, the company specializes in the discovery, development, and commercialization of innovative therapeutics targeting infectious diseases, cancer, and complications related to diabetes. Its product portfolio includes Nemonoxacina, an anti-infection drug effective against drug-resistant pathogens; Taigexyn, a non-fluorinated quinolone antibiotic; and TG-1000, which treats influenza A and B. Additionally, TaiGen develops stem cell mobilizers for therapeutic applications in leukemia and offers a range of inhibitors for hepatitis C, as well as treatments for various bacterial infections. The company's focus on addressing unmet medical needs positions it as a significant player in the pharmaceutical industry.